Medigene AG announced the expansion of the senior management team by appointing Dr. Dr. Olav Zilian as Senior Vice President Corporate Development, Dr. Kai Pinkernell as Senior Vice President/Chief Medical Officer (CMO) and Dr. Markus Dangl as Senior Vice President Research & Pre-Clinical Development.
Market Closed -
Other stock markets
|
Pre-market 01:32:01 | |||
1.22 EUR | +1.67% | 1.23 | +0.82% |
05-21 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
05-15 | Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.00% | 39.04M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene AG Announces Management Changes